Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

Immunotherapy-chemotherapy combination of eftilagimod alfa (efti) and paclitaxel led to strong objective response rates and ...

Dr Avan Armaghani discusses earlier use of ADCs, artificial intelligence for recurrence prediction, and new endocrine therapy ...

Imvax has shrugged off the failure of its phase 2b brain cancer trial to hit its primary endpoint, reporting evidence of ...

But the biotech’s newest update has failed to garner the same investor enthusiasm, with the company’s stock nearly halved following the data drop.

About 10% of adolescents and young adults treated for solid tumors have a metastatic recurrence, with 5-year rates surpassing ...

Younger women are being diagnosed with breast cancer more often than screening guidelines anticipate. Many of these cancers ...

Though none of the blood tests have been approved by federal regulators — and they cost hundreds of dollars — people are ...

New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test ...

The prospect of diagnosing cancer through painless methods—such as a simple AI-assisted blood or urine test that detects tiny ...